Clonotype analysis of cytomegalovirus-specific cytotoxic T lymphocytes.
Cytotoxic T lymphocytes (CTL) control the replication of human cytomegalovirus (CMV). Previous studies assessed the clonotypic composition of CTL specific for individual immunodominant peptides within a certain HLA context. Such an approach has inherent limitations and may not assess the true clonal CTL response in vivo. Here, the clonotypic composition of CMV-specific CTL was determined in HLA-A2, CMV-seropositive kidney transplant recipients and healthy blood donors after stimulation of peripheral blood mononuclear cells with either a pp65 whole-peptide pool or a single immunodominant peptide. Even after stimulation with the whole peptide pool, CMV-specific CTL remained monoclonal or oligoclonal. Regarding intraindividual variation, the CDR3 motifs of the dominant clones were identical to those observed in CTL generated by the single immunodominant peptide. Sequencing of the CDR3 regions demonstrated significant interindividual variation; however, structural homology was observed for immunodominant clonotypes in three individuals. In conclusion, the highly focused T cell receptor repertoire found after stimulation with either a single immunodominant peptide or a peptide pool demonstrates a pivotal role for immunodominant epitopes in the generation of a clonal repertoire. These results provide new insights into the regulation of CMV clonal dominance and may contribute to the design and monitoring of adoptive immunotherapy.
Babel
Nina
N
Experimental Haematology and Hematopoiesis Section, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, Ohio, USA. nina.babel@charite.de
Brestrich
Gordon
G
Gondek
Lukasz P
LP
Sattler
Arne
A
Wlodarski
Marcin W
MW
Poliak
Nina
N
Bethke
Nicole
N
Thiel
Andreas
A
Hammer
Markus H
MH
Reinke
Petra
P
Maciejewski
Jaroslaw P
JP
D000911:Antibodies, Monoclonal / Q000737:chemistry; D000941:Antigens / Q000737:chemistry; D018414:CD8-Positive T-Lymphocytes / Q000378:metabolism; D003587:Cytomegalovirus / Q000235:genetics / Q000378:metabolism*; D005434:Flow Cytometry / Q000379:methods; D006680:HLA Antigens / Q000378:metabolism; D015789:HLA-A2 Antigen / Q000096:biosynthesis; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D016219:Immunotherapy, Adoptive / Q000379:methods; D016030:Kidney Transplantation / Q000276:immunology; D010455:Peptides / Q000737:chemistry; D010750:Phosphoproteins / Q000737:chemistry; D011948:Receptors, Antigen, T-Cell / Q000378:metabolism; D013602:T-Lymphocytes, Cytotoxic / Q000378:metabolism* / Q000821:virology*; D014763:Viral Matrix Proteins / Q000737:chemistry
D000911:Antibodies, Monoclonal; D000941:Antigens; D006680:HLA Antigens; D015789:HLA-A2 Antigen; D010455:Peptides; D010750:Phosphoproteins; D011948:Receptors, Antigen, T-Cell; D014763:Viral Matrix Proteins; C065418:cytomegalovirus matrix protein 65kDa
J Immunol. 2007 Apr 1;178(7):4455-65
17372003
J Virol. 2000 Oct;74(19):9144-51
10982361
Blood. 1997 Sep 1;90(5):1751-67
9292508
Br J Haematol. 2001 Jan;112(1):189-94
11167801
Blood. 2002 Jan 1;99(1):213-23
11756174
J Virol. 1999 Mar;73(3):2099-108
9971792
Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8785-90
9671756
Curr Opin Immunol. 1998 Aug;10(4):393-6
9722914
Transplantation. 1992 Nov;54(5):887-96
1332226
Eur J Immunol. 2005 Jul;35(7):2250-8
15915543
Am J Transplant. 2006 Mar;6(3):625-31
16468975
Eur J Immunol. 1993 Jul;23(7):1417-21
8391985
Transplantation. 2004 Jun 27;77(12):1866-75
15223905
J Exp Med. 1997 Jul 7;186(1):83-9
9207000
Blood. 2005 Oct 15;106(8):2769-80
15914562
J Immunol Methods. 2003 Jan 15;272(1-2):23-34
12505709
J Immunol. 2005 Nov 1;175(9):6123-32
16237109
Immunology. 1999 Nov;98(3):443-9
10583606
Leukemia. 2005 Feb;19(2):217-22
15668701
Eur J Immunol. 2000 Jun;30(6):1676-82
10898504
J Immunol. 2002 Aug 15;169(4):1984-92
12165524
Immunity. 1998 Feb;8(2):177-87
9491999
Blood. 2006 Oct 15;108(8):2632-41
16614248
J Immunol. 2000 Jun 1;164(11):5771-81
10820255
Nat Med. 1998 Aug;4(8):975-8
9701254
J Exp Med. 1995 Jan 1;181(1):79-91
7807026